Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
P =0.89), prostate cancer (RR, 0.53
Case Study 2: Comparative Efficacy of Multi-Agonists Semaglutide Single agonist: Targets GLP-1 to boost insulin secretion and reduce appetite
This can be repeated several times daily as needed
Frequently asked questions (FAQs) No, GLP-1 is not the same as Ozempic, but Ozempic is a type of GLP-1 medication
For some patients, a GLP-1 or related medication may be appropriate